Pin Therapeutics
Seongnam
About Pin Therapeutics
Pin Therapeutics is founded in Feb 2017, fast growing stage with member composition of 25% in USA and 75% in Korea. Drug discovery leaderships are from global pharma and biotech companies along with talented scientists both in Korea and USA. * Active Focus - PinE3: E3 ligase screening cascade for identifying novel warheads - PinGLUE: Assay cascade for molecular glue degrader screening * Programs - Selective Molecular Glue Degrader (CK1╬▒) - Molecular Glue Degrader Programs (5-6 Undisclosed) - PROTAC Program (1 Undisclosed)
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $48.0M
- Funding stage: Late Stage Venture
- Last round: Series C (Dec 2024)
- Website: pintherapeutics.com
- Phone: +82 392-87-00875
Industries & Categories
Biotechnology, Manufacturing, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/pin-therapeutics-98043 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.